Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery

Yiyu Zou, Isamu Horikoshi, Tokuzou Kasagi, Xueqiu Gu, Roman Perez-Soler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The plasma levels, organ distribution, and in vivo antitumor activity of free and liposomal doxorubicin injected into the hepatic artery of rats bearing W256 liver tumors were studied. The administration of liposomal doxorubicin resulted in liver-tumor and liver-parenchyma doxorubicin areas under the curve (AUCs) that were 4.7-and 3.8-fold, respectively, those obtained after the administration of free doxorubicin. Spleen and plasma AUCs were also increased by 2.8 and 2.5 times, respectively, following administration of the liposomal form. In contrast, liposomal doxorubicin did not affect heart AUCs; peak doxorubicin levels in heart tissue were three times lower in animals treated with liposomal doxorubicin. Following treatment with the liposomal form, the cumulative urinary excretion of doxorubicin at 8 h was 38 times lower. In good correlation with these findings, liposomal doxorubicin (2.35 mg/kg on day 7) was more effective than free doxorubicin against liver W256 tumors as measured by tumor-growth inhibition at 5 days after treatment (16% for liposomal doxorubicin versus -53.7% for free doxorubicin, P<0.05) and increased life span (ILS; 108% for liposomal doxorubicin versus 27% for free doxorubicin, P<0.05). These results demonstrate that as compared with free doxorubicin, the administration of liposomal doxorubicin into the hepatic artery results in higher drug levels in the liver tumor and enhanced antitumor activity while maintaining the cardioprotective effect of the liposome carrier as suggested by the decreased peak drug levels measured in the heart tissue.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume31
Issue number4
DOIs
StatePublished - Jul 1993
Externally publishedYes

Fingerprint

Hepatic Artery
Doxorubicin
Liver
Tumors
Area Under Curve
Neoplasms
Bearings (structural)
Tissue
Plasmas
liposomal doxorubicin
Liposomes
Pharmaceutical Preparations
Rats
Animals
Spleen
Therapeutics
Growth

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery. / Zou, Yiyu; Horikoshi, Isamu; Kasagi, Tokuzou; Gu, Xueqiu; Perez-Soler, Roman.

In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. 4, 07.1993, p. 313-318.

Research output: Contribution to journalArticle

@article{c0149a551dd0488fb19e7ad8a6227b61,
title = "Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery",
abstract = "The plasma levels, organ distribution, and in vivo antitumor activity of free and liposomal doxorubicin injected into the hepatic artery of rats bearing W256 liver tumors were studied. The administration of liposomal doxorubicin resulted in liver-tumor and liver-parenchyma doxorubicin areas under the curve (AUCs) that were 4.7-and 3.8-fold, respectively, those obtained after the administration of free doxorubicin. Spleen and plasma AUCs were also increased by 2.8 and 2.5 times, respectively, following administration of the liposomal form. In contrast, liposomal doxorubicin did not affect heart AUCs; peak doxorubicin levels in heart tissue were three times lower in animals treated with liposomal doxorubicin. Following treatment with the liposomal form, the cumulative urinary excretion of doxorubicin at 8 h was 38 times lower. In good correlation with these findings, liposomal doxorubicin (2.35 mg/kg on day 7) was more effective than free doxorubicin against liver W256 tumors as measured by tumor-growth inhibition at 5 days after treatment (16{\%} for liposomal doxorubicin versus -53.7{\%} for free doxorubicin, P<0.05) and increased life span (ILS; 108{\%} for liposomal doxorubicin versus 27{\%} for free doxorubicin, P<0.05). These results demonstrate that as compared with free doxorubicin, the administration of liposomal doxorubicin into the hepatic artery results in higher drug levels in the liver tumor and enhanced antitumor activity while maintaining the cardioprotective effect of the liposome carrier as suggested by the decreased peak drug levels measured in the heart tissue.",
author = "Yiyu Zou and Isamu Horikoshi and Tokuzou Kasagi and Xueqiu Gu and Roman Perez-Soler",
year = "1993",
month = "7",
doi = "10.1007/BF00685677",
language = "English (US)",
volume = "31",
pages = "313--318",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery

AU - Zou, Yiyu

AU - Horikoshi, Isamu

AU - Kasagi, Tokuzou

AU - Gu, Xueqiu

AU - Perez-Soler, Roman

PY - 1993/7

Y1 - 1993/7

N2 - The plasma levels, organ distribution, and in vivo antitumor activity of free and liposomal doxorubicin injected into the hepatic artery of rats bearing W256 liver tumors were studied. The administration of liposomal doxorubicin resulted in liver-tumor and liver-parenchyma doxorubicin areas under the curve (AUCs) that were 4.7-and 3.8-fold, respectively, those obtained after the administration of free doxorubicin. Spleen and plasma AUCs were also increased by 2.8 and 2.5 times, respectively, following administration of the liposomal form. In contrast, liposomal doxorubicin did not affect heart AUCs; peak doxorubicin levels in heart tissue were three times lower in animals treated with liposomal doxorubicin. Following treatment with the liposomal form, the cumulative urinary excretion of doxorubicin at 8 h was 38 times lower. In good correlation with these findings, liposomal doxorubicin (2.35 mg/kg on day 7) was more effective than free doxorubicin against liver W256 tumors as measured by tumor-growth inhibition at 5 days after treatment (16% for liposomal doxorubicin versus -53.7% for free doxorubicin, P<0.05) and increased life span (ILS; 108% for liposomal doxorubicin versus 27% for free doxorubicin, P<0.05). These results demonstrate that as compared with free doxorubicin, the administration of liposomal doxorubicin into the hepatic artery results in higher drug levels in the liver tumor and enhanced antitumor activity while maintaining the cardioprotective effect of the liposome carrier as suggested by the decreased peak drug levels measured in the heart tissue.

AB - The plasma levels, organ distribution, and in vivo antitumor activity of free and liposomal doxorubicin injected into the hepatic artery of rats bearing W256 liver tumors were studied. The administration of liposomal doxorubicin resulted in liver-tumor and liver-parenchyma doxorubicin areas under the curve (AUCs) that were 4.7-and 3.8-fold, respectively, those obtained after the administration of free doxorubicin. Spleen and plasma AUCs were also increased by 2.8 and 2.5 times, respectively, following administration of the liposomal form. In contrast, liposomal doxorubicin did not affect heart AUCs; peak doxorubicin levels in heart tissue were three times lower in animals treated with liposomal doxorubicin. Following treatment with the liposomal form, the cumulative urinary excretion of doxorubicin at 8 h was 38 times lower. In good correlation with these findings, liposomal doxorubicin (2.35 mg/kg on day 7) was more effective than free doxorubicin against liver W256 tumors as measured by tumor-growth inhibition at 5 days after treatment (16% for liposomal doxorubicin versus -53.7% for free doxorubicin, P<0.05) and increased life span (ILS; 108% for liposomal doxorubicin versus 27% for free doxorubicin, P<0.05). These results demonstrate that as compared with free doxorubicin, the administration of liposomal doxorubicin into the hepatic artery results in higher drug levels in the liver tumor and enhanced antitumor activity while maintaining the cardioprotective effect of the liposome carrier as suggested by the decreased peak drug levels measured in the heart tissue.

UR - http://www.scopus.com/inward/record.url?scp=0027448407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027448407&partnerID=8YFLogxK

U2 - 10.1007/BF00685677

DO - 10.1007/BF00685677

M3 - Article

C2 - 8422696

AN - SCOPUS:0027448407

VL - 31

SP - 313

EP - 318

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -